Clinical Trial Detail

NCT ID NCT03958383
Title IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Wisconsin, Madison
Indications

melanoma

Therapies

hu14.18-IL2

hu14.18-IL2 + Nivolumab

hu14.18-IL2 + Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.